Biogen Idec reports positive results from Phase II trial of anti-LINGO-1 in acute optic neuritis

9 January 2015
2019_biotech_test_vial_discovery_big

US biotech firm Biogen Idec (Nasdaq: BIIB) has announced positive top-line results from its Phase II trial of anti-LINGO-1 in acute optic neuritis.

The RENEW trial showed treatment with anti-LINGO-1 demonstrated evidence of biological repair of the visual system, and that it demonstrated an improvement in the recovery of optic nerve latency, which was the study’s endpoint. This was measured by full field visual evoked potential (FF-VEP), relative to placebo.

The study showed no effect on secondary endpoints, including change in thickness of the retinal layers (optic nerve neurons and axons) and visual function, as measured by spectral domain optical coherence tomography (SD-OCT) and low contrast letter acuity, respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology